On Trial

November 2010

Phase 1 Study of an Autologous Neo-Urinary Conduit in Subjects Requiring Incontinent Urinary Diversion Following Radical Cystectomy

Tengion, Inc. is developing neo-organs and neo-tissues to meet clinical unmet needs. Tengion is currently conducting a phase I clinical trial to examine whether Neo-Urinary Conduit™, which is made in the laboratory from a combination of a patient’s own cells and other materials, can be used to form a conduit to safely allow urine flow from the kidneys to outside the body after radical cystectomy in patients with bladder cancer.

There are many complications associated with traditional ileal conduit surgery, some of which are directly related to mobilizing bowel tissue and placing it within the urinary tract where it secretes mucus and absorbs urine. The Neo-Urinary Conduit is designed to eliminate the need to use bowel in these patients.

More information on this clinical trial is available at http://clinicaltrials.gov/ct2/show/NCT01087697.

Tengion Contact: Michael Tillinger, MD at 267-960-4831 or michael.tillinger@tengion.com, or Rosemary Keller at 267-960-4860 or rosemary.keller@tengion.com

To view other, current Trials to Note, look at the right hand column of BCAN’s Clinical Trials information page. To see what clinical trials you qualify for, use BCAN’s Clinical Trials Matching Service by calling 800-504-7442 or visit http://www.emergingmed.com/partners/bcan/.